Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports

Search

Descriptive Alt Text

Filters

Showing results 193–200 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
AIM ImmunoTech Inc. Ampligen (AMP-270) Pancreatic cancer Phase 2 Trial Planned Intravenous Oncology
AIM ImmunoTech Inc. IP Ampligen (rintatolimod) and interferon-alpha (IFNα) Cisplatin resistant advanced recurrent ovarian cancer Phase 2 Data Released intraperitoneal Oncology
AIM ImmunoTech Inc. Ampligen and celecoxib Primary PD-1/PD-L1 resistant melanoma Phase 2 Trial Planned Ampligen intravenous Celecoxib oral Oncology
AIM ImmunoTech Inc. Ampligen, Intron A Prostate Cancer Phase 2 Ampligen intravenous Intron A subcutaneous or intramuscular Oncology
AIM ImmunoTech Inc. Ampligen (AMP-511) Post-COVID-19 conditions Phase 2 Ongoing Intravenous COVID-19
AIM ImmunoTech Inc. Ampligen (AMP-518) Post-COVID conditions Phase 2 Data Released Intravenous N/A
AIM ImmunoTech Inc. Ampligen, Intron A, and celecoxib Colorectal cancer Phase 2 Ampligen intravenous Intron A subcutaneous intramuscular intravenous celecoxib oral Oncology
Ainos Inc. VELDONA Sjögren's syndrome Phase 3 Ongoing oral Immunology